Intellia Therapeutics shares rallied 7.6% following FDA acceptance of its CRISPR-based HAE treatment under Priority Review with a March 2027 decision date, and a $400 million debt facility secured in September. However, the stock carries a Hold rating as earnings estimate revisions remain unchanged, and the company faces declining revenues and quarterly losses.

Adma Biologics (ADMA) outperformed the broader market on October 8, 2026, rising 1.87% to $10.33 while the S&P 500 declined 0.47%. The infectious disease drug developer has gained 7.3% over the past month and is expected to report EPS of $0.19 (up 18.75% YoY) with revenue of $139.8 million (up 4.16% YoY). The company trades at a Forward P/E of 13.06, a discount to its industry average of 23.26, and currently holds a Zacks Rank of #3 (Hold).

ADMA Biologics has attracted investor attention with shares returning +7.3% over the past month, outperforming the S&P 500's +1.4% gain. The company is expected to post earnings of $0.19 per share for the current quarter (+18.8% YoY) and $0.78 for the fiscal year (+30% YoY). However, with a Zacks Rank #3 (Hold) rating and consensus estimates remaining unchanged over the past month, the stock is expected to perform in line with the broader market in the near term. The company trades at a valuation discount to peers with a B grade on the Value Style Score.

While brokers give Adma Biologics an average recommendation of 2.00 (Buy) based on five firms' ratings, the article cautions that brokerage recommendations often have positive bias due to institutional vested interests. The company's Zacks Rank is #3 (Hold), as earnings estimates have remained unchanged, suggesting the stock may perform in line with the broader market in the near term.

Rosen Law Firm is encouraging investors who suffered losses exceeding $100,000 in Peabody Energy Corporation (BTU) to join a securities class action lawsuit. The lawsuit alleges that Peabody Energy provided misleading statements about its Centurion mine operations, with actual Q1 2026 output reaching only 250,000 tons versus previously estimated 700,000 tons. The lead plaintiff deadline is August 24, 2026. Similar class actions are also being pursued against ADMA Biologics and Microvast Holdings.

Rosen Law Firm reminds investors of the August 10, 2026 deadline to join a securities class action lawsuit against ADMA Biologics. The lawsuit alleges the company made materially false statements regarding undisclosed related party transactions, channel stuffing, and inadequate internal controls that artificially inflated revenue during the class period from August 9, 2024 to March 25, 2026.

ADMA Biologics is facing a securities fraud class action lawsuit alleging misrepresentations regarding financial condition, revenue recognition, and undisclosed related-party transactions. A short-seller report in March 2026 revealed channel stuffing and improper accounting practices, causing the stock to plunge 31.6% over two trading days. The lawsuit covers the period from August 9, 2024 to March 25, 2026, with a lead plaintiff deadline of August 10, 2026.

ADMA Biologics is facing a securities class action lawsuit alleging the company made false statements regarding undisclosed related party transactions, channel stuffing schemes, and inadequate internal controls. A Culper Research report claimed ADMA's reported 20% growth in 2025 was artificially inflated, with actual revenue declining 3% when adjusted for extended payment terms. The stock declined over 16% following the report, and an additional 13% after a Cantor Fitzgerald downgrade. Investors with substantial losses can seek lead plaintiff status by Monday, August 10, 2026.

Class action lawsuits have been filed against four publicly-traded companies for alleged securities fraud. Futu Holdings faces allegations of non-compliance with Chinese regulatory requirements, First Solar allegedly overstated its ability to manage tariff impacts, Black Rock Coffee Bar allegedly misrepresented its expansion strategy and cannibalization effects, and ADMA Biologics allegedly engaged in undisclosed related party transactions and channel stuffing. Investors have until mid-to-late August 2026 to file lead plaintiff motions.

A class action lawsuit has been filed against ADMA Biologics, Inc. following allegations of channel stuffing and undisclosed related party transactions. Culper Research reported that ADMA induced distributors to stock excess inventory through rebates and extended payment terms to artificially inflate revenue growth. The stock fell 29.1% on the news, and investors have until August 10, 2026 to file a lead plaintiff motion.

A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. alleging misrepresentations concerning financial condition, revenue recognition, and undisclosed related-party transactions. The lawsuit covers the period from August 9, 2024 to March 25, 2026. Following a short-seller report by Culper Research on March 24, 2026 revealing channel stuffing and undisclosed distributor Genesis BioPharma, ADMA's stock plummeted 31.6% over two trading days, with further declines following a rating downgrade.

Kahn Swick & Foti, LLC announces a class action securities lawsuit against ADMA Biologics, Inc. for investors who purchased securities between August 9, 2024 and March 25, 2026. The lawsuit alleges the company and its executives failed to disclose material information, including undisclosed related party transactions, channel stuffing, and inadequate internal controls. The application deadline to request lead plaintiff status is August 10, 2026.